ASLAN Pharmaceuticals Limited
ASLN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $12 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $12 | -$0 | -$0 | -$0 |
| % Margin | 97.1% | – | – | – |
| R&D Expenses | $42 | $38 | $22 | $9 |
| G&A Expenses | $13 | $10 | $12 | $7 |
| SG&A Expenses | $13 | $10 | $12 | $7 |
| Sales & Mktg Exp. | -$0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $1 |
| Operating Expenses | $55 | $48 | $34 | $16 |
| Operating Income | -$44 | -$48 | -$34 | -$16 |
| % Margin | -364.5% | – | – | – |
| Other Income/Exp. Net | -$0 | -$3 | $2 | -$0 |
| Pre-Tax Income | -$44 | -$51 | -$32 | -$17 |
| Tax Expense | $0 | $0 | $3 | $1 |
| Net Income | -$44 | -$51 | -$35 | -$18 |
| % Margin | -368.5% | – | – | – |
| EPS | -10.76 | -14.72 | -10.64 | -9.32 |
| % Growth | 26.9% | -38.3% | -14.2% | – |
| EPS Diluted | -10.76 | -14.72 | -10.64 | -9.32 |
| Weighted Avg Shares Out | 4 | 3 | 3 | 2 |
| Weighted Avg Shares Out Dil | 4 | 3 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4 | $4 | $2 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$39 | -$47 | -$29 | -$15 |
| % Margin | -328.4% | – | – | – |